Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

NCT05325281 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT05325281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05325281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2022
Completion date
July 8, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas adenocarcinoma